JAK2 and acquired polycythemia vera: In humans, most patients with polycythemia vera (PV), one-half of the cases of essential thrombocythemia (ET), and other myeloproliferative neoplasms (MPNs) cases possess an JAK2 p.V617F mutation (exon 12) [34] leading to constitutive activity of the JAK2 gene-encoded tyrosine kinase.